CERo Therapeutics (NASDAQ:CERO) Sets New 1-Year Low – What’s Next?

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) shares hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $3.35 and last traded at $3.35, with a volume of 174874 shares changing hands. The stock had previously closed at $5.23.

CERo Therapeutics Stock Performance

The stock has a 50-day moving average price of $0.12 and a 200 day moving average price of $0.14.

Insiders Place Their Bets

In related news, major shareholder Bioventures Opportunities G. Yk sold 29,989 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.00, for a total transaction of $179,934.00. Following the completion of the sale, the insider now owns 130,051 shares in the company, valued at $780,306. The trade was a 18.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 96,800 shares of company stock worth $854,409 in the last 90 days. Corporate insiders own 18.00% of the company’s stock.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.